Abstract

BackgroundWe investigated the association between oxcarbazepine (OXC)-induced maculopapular eruption (MPE) and HLA-B alleles in a northern Han Chinese population, and conducted an analysis of clinical risk factors for OXC-MPE.MethodsForty-two northern Han Chinese patients who had been treated with OXC in Changchun, China were genotyped. Among them were 14 cases with OXC-induced MPE; the remaining 28 were OXC-tolerant. The HLA-B allele frequencies of the normal control group were found in the Allele Frequency Net Database. Polymerase chain reaction-sequence specific primer( PCR-SSP )was used for HLA-B*1502 testing and direct sequencing for four-digit genotype determination.ResultsFour-digit allele sequencing showed that there was no statistically significant difference in the frequency of the HLA-B*1502 allele between the OXC-MPE and OXC-tolerant controls (3.6% versus 7.5%, OR = 0.38, 95% CI = 0.04–3.40, P = 0.65), as well as between OXC-MPE and normal controls (3.6% versus 2.4%, OR = 1.54, 95% CI = 0.20–11.73, P = 0.49). However, a significant difference in the frequency of HLA-B*3802 alleles was found between the MPE group and normal controls (10.7% versus 1.9%, OR = 6.329, 95% CI = 1.783-22.460, P = 0.018). There was no significant difference in terms of age, gender, or final OXC dose between the OXC-MPE and OXC-tolerant groups.ConclusionsThere was no significant association between OXC-MPE and HLA-B*1502 in the northern Han Chinese population in our study. Instead, HLA-B*3802 was found to be a potential risk factor for OXC-MPE.

Highlights

  • We investigated the association between oxcarbazepine (OXC)-induced maculopapular eruption (MPE) and HLA-B alleles in a northern Han Chinese population, and conducted an analysis of clinical risk factors for OXC-induced MPE (OXC-MPE)

  • Fourteen patients who had been diagnosed with OXCinduced MPE (9 females, 5 males; mean age 34.43 ± 12.10 y) and 28 patients who received OXC for at least 3 months without any evidence of adverse drug reactions (17 females, 11 males; mean age 34.04 ± 12.85 y) were enrolled as cases (OXC-MPE) and tolerant controls (OXC-tolerant), respectively

  • In the present study we found no association between OXC-induced MPE and HLA-B*1502 in our northern Han Chinese patients

Read more

Summary

Introduction

We investigated the association between oxcarbazepine (OXC)-induced maculopapular eruption (MPE) and HLA-B alleles in a northern Han Chinese population, and conducted an analysis of clinical risk factors for OXC-MPE. The clinical effectiveness of OXC is similar to that of CBZ, but with fewer adverse drug reactions (ADRs), which is attributed to their different metabolic pathways [1]. A common side effect associated with AED use is rash, and has been the leading cause of withdrawal from some AED trials [2,3,4]. Cutaneous adverse drug reactions (cADRs) induced by AEDs range from mild maculopapular eruption (MPE) and hypersensitivity syndrome, to the more severe Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Among these cADRs, MPE is the most common [7], and is generally considered an initial form of the other, more severe, cADRs

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call